SCHEMBL474580

SCHEMBL474580

COc1c(C(=O)O)ccc(-c2ccc(C(C)C(O)(c3ccc4c(c3)n(C)c(=O)n4C)C(F)(F)F)cc2)c1Cl

nearest known ligand 0.38

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 6/20 0.38
AKR1C2 P52895 6/20 0.38
CMA1 P23946 6/20 0.35
GCGR P47871 4/20 0.33
APP P05067 1/20 0.32
CYP2C19 P33261 1/20 0.32
BRD4 O60885 1/20 0.31
BRPF1 P55201 1/20 0.31
GAA P10253 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL474508 0.84 SRD5A2 (0.41) AKR1C3AKR1C2GCGRBRD4BRPF1
SCHEMBL12163988 0.79 RORC (0.35) AKR1C3AKR1C2CMA1BRD4BRPF1
SCHEMBL474584 0.79 RORC (0.35) AKR1C3AKR1C2CMA1BRD4BRPF1
SCHEMBL474325 0.78 CMA1 (0.36) AKR1C2CMA1CYP2C19BRD4BRPF1
SCHEMBL12163974 0.78 CMA1 (0.36) AKR1C2CMA1CYP2C19BRD4BRPF1
SCHEMBL474600 0.76 CMA1 (0.36) AKR1C3AKR1C2CMA1CYP2C19BRD4
SCHEMBL474419 0.76 GRIK1 (0.36) AKR1C3AKR1C2CMA1BRD4BRPF1
SCHEMBL12163989 0.76 GRIK1 (0.36) AKR1C3AKR1C2CMA1BRD4BRPF1
SCHEMBL474247 0.75 TNKS2 (0.39) AKR1C3AKR1C2GCGRBRD4BRPF1
SCHEMBL12163997 0.75 TNKS2 (0.39) AKR1C3AKR1C2GCGRBRD4BRPF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2411365-A1 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2012-02-01 EP disclosed
WO-2010108903-A1 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-30 WO disclosed